公开(公告)号：US20180051089A1

公开(公告)日：2018-02-22

申请号：US15546623

申请日：2016-01-25

申请人： Cellectis

发明人： Roman GALETTO ,  Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON ,  Mathieu SIMON

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783

CPC分类号： C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

摘要： The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.

公开(公告)号：US20160333094A1

公开(公告)日：2016-11-17

申请号：US15111441

申请日：2015-01-14

申请人： CELLECTIS

发明人： Philippe DUCHATEAU ,  Julien VALTON

IPC分类号： C07K16/28 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/705 ,  C07K14/725

CPC分类号： C07K16/2803 ,  A61K35/17 ,  A61K38/00 ,  A61K39/001112 ,  A61K2039/5156 ,  A61K2039/804 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2510/00

摘要： The present invention relates to a new generation of chimeric antigen receptors (CAR), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a VNAR polypeptide derived from monomeric antibodies from cartilaginous fish. Such CARs, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.

摘要翻译： 本发明涉及单链或多链形式的新一代嵌合抗原受体（CAR），其特异性为所需抗原，由来自软骨鱼的单体抗体衍生的VNAR多肽赋予其特异性。 旨在将免疫细胞特异性转向所选择的不希望的恶性细胞的这种CAR是紧凑的，因此特别适用于靶向中空抗原，例如存在于耐药细胞表面的外排泵的离子通道。 本发明包括多核苷酸，编码所述多链CAR的载体和在其表面表达它们的分离细胞，特别是其用于免疫治疗。

公开(公告)号：US20190338273A1

公开(公告)日：2019-11-07

申请号：US16379073

申请日：2019-04-09

申请人： CELLECTIS

发明人： Philippe DUCHATEAU ,  Julien VALTON

IPC分类号： C12N15/10 ,  G01N33/53 ,  C12N9/22 ,  C07K14/47

摘要： The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.

公开(公告)号：US20190290694A1

公开(公告)日：2019-09-26

申请号：US16466327

申请日：2017-12-20

申请人： CELLECTIS

发明人： Anne-Sophie GAUTRON ,  Philippe DUCHATEAU ,  Laurent POIROT ,  Julien VALTON

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N5/071 ,  A61K31/69 ,  C07K14/725

摘要： The present invention relates to gene editing methods to engineer primary immune cells that are made resistant to proteasome inhibitors, such as Bortezomib, Carfilzomib, Ixazomib, Marizomib, Delanzomib or Oporozomib, for their use in cell immunotherapy in combination with proteasome inhibitor treatments.

公开(公告)号：US20180009895A1

公开(公告)日：2018-01-11

申请号：US15546633

申请日：2016-01-25

申请人： Cellectis

发明人： Julianne SMITH ,  Julien VALTON ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Arvind RAJPAL ,  Barbra Johnson SASU

IPC分类号： C07K16/28 ,  A61K39/00 ,  C07K16/30 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/00

CPC分类号： C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

摘要： The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.

公开(公告)号：US20170073423A1

公开(公告)日：2017-03-16

申请号：US15106783

申请日：2014-12-19

申请人： CELLECTIS

发明人： Alexandre JUILLERAT ,  Claudia BERTONATI ,  Julien VALTON ,  Philippe DUCHATEAU ,  Laurent POIROT

IPC分类号： C07K16/30 ,  C07K16/28 ,  C07K14/47

CPC分类号： C07K16/30 ,  C07K14/47 ,  C07K16/2863 ,  C07K16/468 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/30 ,  C12N2510/02

摘要： The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals. The invention also relates to new designed chimeric antigen receptors which are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties and the hypoxia condition. The present invention also relates to cells obtained by the present method, in particular T-cells, comprising said chimeric antigen receptors for use in cancer treatments.

摘要翻译： 本发明涉及免疫治疗免疫细胞的设计方法。 特别地，所述免疫细胞用嵌合抗原受体工程化，其通过缺氧和配体细胞外结合的组合被激活作为输入信号。 本发明还涉及新设计的嵌合抗原受体，其能够将免疫细胞特异性和反应性转向利用配体结合结构域性质和缺氧条件的选定靶标。 本发明还涉及通过本方法获得的细胞，特别是包含用于癌症治疗的所述嵌合抗原受体的T细胞。

公开(公告)号：US20240228636A1

公开(公告)日：2024-07-11

申请号：US18481797

申请日：2023-10-05

申请人： Cellectis ,  Allogene Therapeutics, Inc.

发明人： Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  G01N15/01 ,  G01N15/10 ,  G01N15/1031 ,  G01N15/14 ,  G01N15/149

CPC分类号： C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001176 ,  A61K39/39558 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  G01N15/1031 ,  G01N15/14 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00 ,  G01N2015/016 ,  G01N2015/1006 ,  G01N2015/1028 ,  G01N15/149

摘要： A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.

公开(公告)号：US20230248825A1

公开(公告)日：2023-08-10

申请号：US18005284

申请日：2021-07-23

申请人： CELLECTIS S.A.

发明人： Shipra DAS ,  Sumin JO ,  Alexandre JUILLERAT ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC分类号： A61K39/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12N5/0783 ,  C12N15/113 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/4633 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N5/0636 ,  A61K39/4611 ,  A61K39/4643 ,  C12N15/1138 ,  A61K39/3955 ,  A61K39/4631 ,  A61P35/00 ,  C12N2800/80 ,  C12N2310/20 ,  C12N2506/11 ,  C12N2501/515 ,  C12N2501/51 ,  C12N2501/2302 ,  A61K2039/5158 ,  C12N2310/531 ,  C12N2310/14

摘要： The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.

公开(公告)号：US20210128613A1

公开(公告)日：2021-05-06

申请号：US16629506

申请日：2018-07-20

申请人： CELLECTIS

发明人： Philippe DUCHATEAU ,  Anne-Sophie GAUTRON ,  Laurent POIROT ,  Julien VALTON

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N15/113 ,  C07K16/28 ,  A61K39/395

摘要： The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.

公开(公告)号：US20160361359A1

公开(公告)日：2016-12-15

申请号：US15037988

申请日：2014-11-21

申请人： CELLECTIS

发明人： Julien VALTON ,  Philippe DUCHATEAU ,  David SOURDIVE

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61K31/7076

摘要： The present invention relates to the use of “off-the-shelf” allogeneic therapeutic cells for immunotherapy in conjunction with chemotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering allogeneic T-cell resistant to chemotherapeutic agents. The therapeutic benefits afforded by this strategy should be enhanced by the synergistic effects between chemotherapy and immunotherapy. In particular, the present invention relates to a method for modifying T-cells by inactivating at least one gene encoding T-cell receptor component and by modifying said T-cells to confer drug resistance. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.

摘要翻译： 本发明涉及“现成”同种异体治疗性细胞用于免疫治疗与化疗联合治疗癌症患者的用途。 特别地，本发明人开发了一种对化疗药物耐药的同种异体T细胞的方法。 通过化学疗法和免疫治疗之间的协同效应，可以提高该策略提供的治疗效果。 特别地，本发明涉及通过使至少一种编码T细胞受体成分的基因失活并通过修饰所述T细胞以赋予耐药性来修饰T细胞的方法。 本发明开启了治疗癌症的标准和负担得起的过继免疫治疗策略的方法。